Assessment of myocardial viability with a positron coincidence gamma camera using fluorodeoxyglucose in comparison with dedicated pet

Nuclear Medicine Communications

Volumn 24, Issue 4, 2003, Pages 367-374

  Tian, M ^a   Koyama, K ^a   Zhang, H ^a   Oriuchi, N ^a   Higuchi, T ^a   Endo, K ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Coincidence detection; FDG; Gamma camera; Myocardial viability; PET

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING ORGAN SYSTEMS; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HEART; HEART INFARCTION; HEART MUSCLE; HUMAN; INSTRUMENTATION; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTILLATION CAMERA; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; GAMMA CAMERAS; HEART; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TISSUE SURVIVAL; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1542440430     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200304000-00005     Document Type: Article

References (24)

1. Topol EJ. Comprehensive cardiovascular medicine. Philadelphia: Lippincott-Raven, 1998; 2: 1587-1613.
2. 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation 1983; 67: 766-788.
3. Schwaiger M, Brunken R, Grover-Mckay M, et al. Regional myocardial metabolism in patients with acute myocardial infarction assessed by positron emission tomography. J Am Coll Cardiol 1986; 8: 800-808.
4. Brunken R, Tillisch J, Schwaiger M, et al. Regional perfusion, glucose metabolism, and wall motion in patients with chronic electrocardiographic Q-wave infarctions: evidence for persistence of viable tissue in some infarct regions by positron emission tomography. Circulation 1986; 73: 951-963.
5. 99mTc-MIBI SPET: a comparative study in patients with coronary artery disease. Eur J Nucl Med 1992; 19: 334-342.
6. Tamaki N, Kawamoto M, Tadamura E, et al. Prediction of reversible ischemia after revascularization: perfusion and metabolic studies with positron emission tomography. Circulation 1995; 91: 1697-1705.
7. Conti PS, Keppler JS, Halls JM. Positron emission tomography: a financial and operational analysis. Am J Roentgenol 1994; 162: 1279-1286.
8. Maddahi J, Schelbert H, Brunken R, Di Carlu M. Roleof thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nucl Med 1994; 35: 707-715.
9. Sandler MP, Bax JJ, Patton JA, Visser FC, Martin WH, Wijins W. Fluorine-18-fluorodeoxyglucose cardiac imaging using a modified scintillation camera. J Nucl Med 1998; 39: 2035-2043.
10. Chen EQ, MacIntyre WJ, Go RT, et al. Myocardial viability studies using fluorine-18-FDG SPET: a comparison with fluorine-18-FDG PET. J Nucl Med 1997; 38: 582-586.
11. 18F-Fluorodeoxyglucose single photon emission computed tomography. Can it replace PET and thallium SPET for the assessment of myocardial viability? Circulation 1998; 97: 843-850.
12. Muellehner G, Geagen M, Countryman P, Nellemann P. SPECT scanner with PET coincidence capability. J Nucl Med 1995; 36(Suppl): 70P.
13. Zhang H, Tian M, Oriuchi N, Higuchi T, Tanada S, Endo K. Detection of lung cancer with positron coincidence gamma camera using fluorodeoxyglucose in comparison with dedicated PET. Br J Radiology 2002; 75: 409-416.
14. 18F-Fluorodeoxyglucose imaging with a dual-head coincidence gamma camera for detection of myocardial viability. J Nucl Med 1999; 40: 1884-1892.
15. Sutter JD, Winter FD, Wiele CVD, et al. Cardiac fluorine-18 fluorodeoxyglucose imaging using a dual-head gamma camera with coincidence detection: a clinical pilot study. Eur J Nucl Med 2000; 27: 676-685.
16. Inoue T, Oriuchi N, Kunio M, et al. Accuracy of standardized uptake value measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun 1999; 9: 849-857.
17. Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation 1993; 87: 1-20.
18. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997; 30: 1451-1460.
19. Dilsizian V, Perrone-Filardi P, Arrighi JA, et al. Concordance and discordance between stress-redistribution-reinjection and rest-redistribution thallium imaging for assessing viable myocardium. Comparison with metabolic activity by positron emission tomography. Circulation 1993; 88: 941-952.
20. Altehoefer C, vom Dahl J, Biedermann M, et al. Significance of defect severity in technetium-99m-MIBI SPECT at rest to assess myocardial viability: comparison with fluorine-18-FDG PET. J Nucl Med 1994; 35: 569-574.
21. Soufer R, Dey HM, Ng CK, Zaret BL. Comparison of sestamibi single-photon emission computed tomography with positron emission tomography for estimating left ventricular myocardial viability. Am J Cardiol 1995; 75: 1214-1219.
22. 99mTc-sestamibi with thallium reinjection and [18F]fluorodeoxyglucose. Circulation 1994; 89: 578-587.
23. Beller GA, Zaret BL. Wintergreen panel summaries. J Nucl Cardiol 1999; 6: 93-115.
24. Zhang H, Inoue T, Alyafei S, et al. A basic study on lesion detectability for hot spot imaging of positron emitters by dedicated PET and positron coincidence gamma camera. Ann Nucl Med 2001; 15: 301-306.